2024
Strategies to Deimplement Opioid Prescribing in Primary Care
Quanbeck A, Robinson J, Jacobson N, Li X, Hennessy-Garza R, Landeck J, Cohen A, Madden L, Pulvermacher A, Brown R. Strategies to Deimplement Opioid Prescribing in Primary Care. JAMA Network Open 2024, 7: e2438325. PMID: 39388183, DOI: 10.1001/jamanetworkopen.2024.38325.Peer-Reviewed Original ResearchConceptsCluster randomized clinical trialDeimplementation strategiesMorphine milligram equivalent doseMorphine milligram equivalentsPractice facilitationOpioid prescribingIncreased screeningTreatment agreementsUS health care systemCenters for Disease Control and Prevention guidelinesRandomized clinical trialsUrine drug screensPrimary care clinicsPrimary care settingPrimary outcomeMental health screeningPain-related interferenceHealth care systemHigh-intensity groupEnjoyment of lifeChronic pain managementPrimary careCare clinicsCare settingsHealth screeningIntegrating methadone into primary care settings in Ukraine: effects on provider stigma and knowledge
Bromberg D, Machavariani E, Madden L, Dumchev K, LaMonaca K, Earnshaw V, Pykalo I, Filippovych M, Haddad M, Dvoriak S, Altice F. Integrating methadone into primary care settings in Ukraine: effects on provider stigma and knowledge. Journal Of The International AIDS Society 2024, 27: e26202. PMID: 38379179, PMCID: PMC10879646, DOI: 10.1002/jia2.26202.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidHIV InfectionsHumansMethadonePrimary Health CareSubstance Abuse, IntravenousUkraineConceptsPrimary care clinicsStigma reduction interventionsOpioid agonist therapyClinicians' attitudesStigma constructsHIV preventionReduction interventionsEvidence-based HIV preventionCluster randomized controlled trialEvidence-based carePrimary care settingIntegrated care sitesDirect providersRandomized controlled trialsProvider stigmaCare clinicsCare sitesHIV careCare settingsHealth outcomesClinical staffSubstance use disordersLinear mixed-effects modelsTreatment continuumImprove attitudes
2023
High perceived stress in patients on opioid agonist therapies during rapid transitional response to the COVID-19 pandemic in Ukraine
Galvez S, Altice F, Meteliuk A, Ivasiy R, Machavariani E, Farnum S, Fomenko T, Islam Z, Madden L. High perceived stress in patients on opioid agonist therapies during rapid transitional response to the COVID-19 pandemic in Ukraine. Frontiers In Public Health 2023, 11: 1231581. PMID: 38098837, PMCID: PMC10720365, DOI: 10.3389/fpubh.2023.1231581.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidCOVID-19HumansOpioid-Related DisordersPandemicsStress, PsychologicalSubstance Abuse, IntravenousUkraineConceptsOpioid agonist therapyOpioid use disorderAgonist therapyOAT patientsCOVID-19 pandemicSubstance useTake-home dosingAdditional psychosocial supportHigher perceived stressHigh riskPerceived Stress ScalePsychiatric disordersUse disordersPatientsPatient stressPsychosocial supportCertain subgroupsSevere levelsHigh levelsHealthcare deliveryStress ScalePerceived stressTherapyExtraordinary high levelsDisordersBuilding medication for opioid use disorder prescriber capacity during the opioid epidemic: Prescriber recruitment trends and methods
Molfenter T, Jacobson N, Kim J, Horst J, Kim H, Madden L, Brown R, Haram E, Knudsen H. Building medication for opioid use disorder prescriber capacity during the opioid epidemic: Prescriber recruitment trends and methods. Journal Of Substance Use And Addiction Treatment 2023, 147: 208975. PMID: 36804353, PMCID: PMC10833474, DOI: 10.1016/j.josat.2023.208975.Peer-Reviewed Original ResearchConceptsRecruitment strategiesAdvanced nurse practitionersSUD treatment servicesSUD clinicsPhysician prescribersOpioid epidemicPhysician recruitmentNurse practitionersTreatment servicesPhysician assistantsPatient carePrescribing capacityPrescribersStudy settingClinical resourcesDisorder settingsStudy periodPhysiciansTreatment sitesYear 3Dedicated budgetIndividual factorsBuprenorphineMedicationsClinic“Just fighting for my life to stay alive”: a qualitative investigation of barriers and facilitators to community re-entry among people with opioid use disorder and incarceration histories
Hoffman K, Thompson E, Gaeta Gazzola M, Oberleitner L, Eller A, Madden L, Marcus R, Oberleitner D, Beitel M, Barry D. “Just fighting for my life to stay alive”: a qualitative investigation of barriers and facilitators to community re-entry among people with opioid use disorder and incarceration histories. Addiction Science & Clinical Practice 2023, 18: 16. PMID: 36944998, PMCID: PMC10031976, DOI: 10.1186/s13722-023-00377-y.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidDrug OverdoseHumansMethadoneOpiate Substitution TreatmentOpioid-Related DisordersPrisonersConceptsOpioid use disorderRe-entry experiencesReintegration of peopleSemi-structured qualitative interviewsIncarceration historyExperiences of peoplePerspectives of peopleBasic resourcesThematic analysis approachTransition programCarceral settingsQualitative interviewsLived experienceStable housingStructural barriersSocial challengesFormal transition programQualitative investigationPersistent barriersIncarcerationHistory of incarcerationUse disordersConcrete suggestionsMain themesRe-entry period
2022
The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study
Morford K, Tetrault J, Zhou B, Li F, Gleeson B, Edelman E, Stein M, Barry D, Madden L. The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study. Drug And Alcohol Dependence 2022, 241: 109707. PMID: 36423462, PMCID: PMC9777057, DOI: 10.1016/j.drugalcdep.2022.109707.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidBenzodiazepinesHumansMethadoneOpiate Substitution TreatmentOpioid-Related DisordersRetrospective StudiesConceptsBenzodiazepine exposureRetrospective cohort studyKaplan-Meier analysisTreatment retentionCohort studyCox regressionTreatment durationMedian treatment durationMultivariable Cox regressionCohort of patientsOpioid treatment programsOpioid use disorderLog-rank testSame-day accessDrug Administration recommendationsTreatment discontinuationUrine toxicologyMeier analysisMethadone programsUse disordersPatientsAdministration recommendationsTreatment entryTreatment programTreatment barriersCollaborative learning and response to opioid misuse and HIV prevention in Ukraine during war
Altice FL, Bromberg DJ, Klepikov A, Barzilay EJ, Islam Z, Dvoriak S, Farnum SO, Madden LM. Collaborative learning and response to opioid misuse and HIV prevention in Ukraine during war. The Lancet Psychiatry 2022, 9: 852-854. PMID: 36244353, PMCID: PMC9806953, DOI: 10.1016/s2215-0366(22)00318-2.Peer-Reviewed Original ResearchEnhancing Use of Medications for Opioid Use Disorder Through External Coaching
Molfenter T, Kim H, Kim JS, Kisicki A, Knudsen HK, Horst J, Brown R, Madden LM, Toy A, Haram E, Jacobson N. Enhancing Use of Medications for Opioid Use Disorder Through External Coaching. Psychiatric Services 2022, 74: 265-271. PMID: 36196533, PMCID: PMC10836327, DOI: 10.1176/appi.ps.202100675.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidBuprenorphineHumansNaltrexoneOhioOpiate Substitution TreatmentOpioid-Related DisordersConceptsOpioid use disorderBuprenorphine useControl armUse disordersUse of MOUDUse of medicationsInjectable naltrexoneNaltrexone administrationOutcome measuresCoaching armClinical sitesHealth systemProvider UtilizationTrial periodTreatment agenciesTrialsDelivery modalitiesHealth sitesMedicationsSignificant differencesDisordersArmSimilar patternMOUDNaltrexoneThe development and initial validation of the Russian version of the BASIS-24
Madden L, Farnum S, Bromberg D, Barry D, Mazhnaya A, Fomenko T, Meteliuk A, Marcus R, Rozanova J, Poklad I, Dvoriak S, Altice F. The development and initial validation of the Russian version of the BASIS-24. Addiction Science & Clinical Practice 2022, 17: 65. PMID: 36435811, PMCID: PMC9701377, DOI: 10.1186/s13722-022-00343-0.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidHIV InfectionsHumansOpioid-Related DisordersReproducibility of ResultsRussiaConceptsBASIS-24Addiction treatmentHIV prevention goalsSubset of patientsOpioid use disorderSymptom Identification ScaleMental health statusResultsCronbach’s alpha coefficientsMOUD patientsSeverity InstrumentTuberculosis epidemicEffective treatmentUse disordersHealth statusHealthcare professionalsMental healthPrevention goalsRelationships subscaleTreatment deliveryExploratory principal component analysisOpioidsHIVPatientsAlpha coefficientEECA region
2021
Primary care and medication management characteristics among patients receiving office-based opioid treatment with buprenorphine
Du CX, Shi J, Tetrault JM, Madden LM, Barry DT. Primary care and medication management characteristics among patients receiving office-based opioid treatment with buprenorphine. Family Practice 2021, 39: 234-240. PMID: 34893825, PMCID: PMC8947790, DOI: 10.1093/fampra/cmab166.Peer-Reviewed Original ResearchConceptsOffice-based opioid treatmentPrimary care providersOpioid use disorderUrine toxicologyOpioid treatmentMore primary care providersOutpatient primary care clinicsChronic pain statusChronic viral hepatitisPrimary care clinicsCommon comorbid conditionsPrimary care characteristicsAddiction treatment settingsHigher median numberEvidence-based treatment modelsOBOT patientsOBOT programOlder patientsPain statusViral hepatitisCommon medicationsRetrospective reviewCare clinicsChronic painComorbid conditionsPrescribers’ satisfaction with delivering medications for opioid use disorder
Knudsen HK, Brown R, Jacobson N, Horst J, Kim JS, Kim H, Madden LM, Haram E, Molfenter T. Prescribers’ satisfaction with delivering medications for opioid use disorder. Substance Abuse Treatment, Prevention, And Policy 2021, 16: 78. PMID: 34663379, PMCID: PMC8521499, DOI: 10.1186/s13011-021-00413-7.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidBuprenorphineHumansNaltrexoneNarcotic AntagonistsOpioid-Related DisordersPersonal SatisfactionConceptsType of MOUDOpioid use disorderPrescriber satisfactionPrescriber characteristicsUse disordersXR-naltrexoneBuprenorphine treatmentExtended-release naltrexoneUS opioid epidemicOverall satisfactionRelease naltrexoneGreater overall satisfactionClinical trialsOpioid epidemicMethodsAs partMOUDWeb-based surveyPatient censusPrescribersMedicationsBuprenorphineDisordersTreatmentCurrent studyHigh levelsSuccessful transfer of stable patients on opioid agonist therapies from specialty addiction treatment to primary care settings in Ukraine: A pilot study
Meteliuk A, Galvez S, Fomenko T, Kalandiia H, Iaryi V, Farnum SO, Islam Z, Altice FL, Madden LM. Successful transfer of stable patients on opioid agonist therapies from specialty addiction treatment to primary care settings in Ukraine: A pilot study. Journal Of Substance Use And Addiction Treatment 2021, 134: 108619. PMID: 34579978, DOI: 10.1016/j.jsat.2021.108619.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyPrimary care clinicsPrimary care settingOAT coverageAgonist therapyStable patientsCare clinicsSubstance useCare settingsNegative urine drug testsSpecialty addictions treatmentUrine drug testsSymptom Identification ScaleMental health symptomsAddiction treatment clinicsHIV transmissionPrimary careTreatment clinicsOAT patientsBASIS-24PatientsHealth symptomsEmotional labilityAddiction treatmentPilot studyPsychiatric comorbidity and order of condition onset among patients seeking treatment for chronic pain and opioid use disorder
Barry DT, Beitel M, Cutter CJ, Fiellin DA, Madden LM, Lipkind N, Bollampally P, Liong C, Schottenfeld RS. Psychiatric comorbidity and order of condition onset among patients seeking treatment for chronic pain and opioid use disorder. Drug And Alcohol Dependence 2021, 221: 108608. PMID: 33667784, PMCID: PMC8026725, DOI: 10.1016/j.drugalcdep.2021.108608.Peer-Reviewed Original ResearchConceptsOpioid use disorderChronic painPsychiatric comorbidityCondition onsetUse disordersNonopioid substance use disordersDSM-IV-TR Axis I DisordersFirst groupComorbid chronic painStructured Clinical InterviewAxis I DisordersAxis II disordersSubstance use disordersDSM-IV personality disordersStandardized training protocolSame time groupsPotential treatment implicationsClinical trialsDoctoral-level providersI disordersMultinomial logistic regressionPrimary drugClinical InterviewPainDiagnostic InterviewProject MIMIC (Maximizing Implementation of Motivational Incentives in Clinics): A cluster-randomized type 3 hybrid effectiveness-implementation trial
Becker SJ, Murphy CM, Hartzler B, Rash CJ, Janssen T, Roosa M, Madden LM, Garner BR. Project MIMIC (Maximizing Implementation of Motivational Incentives in Clinics): A cluster-randomized type 3 hybrid effectiveness-implementation trial. Addiction Science & Clinical Practice 2021, 16: 61. PMID: 34635178, PMCID: PMC8505014, DOI: 10.1186/s13722-021-00268-0.Peer-Reviewed Original ResearchMeSH KeywordsAnalgesics, OpioidHumansMotivationOpioid-Related DisordersReimbursement, IncentiveResearch DesignUnited StatesConceptsOpioid treatment programsOpioid use disorderPatient outcomesTreatment programUse disordersContingency managementPutative mediatorsHybrid effectiveness-implementation trialOpioid-related problemsEffectiveness-implementation trialImplementation of CMImplementation outcomesUrgent public health needEvidence-based treatmentsUnit of randomizationPublic health emergencyPublic health needsOpioid abstinenceCM exposurePatient surveyEffective behavioral interventionsClinical trialsProvider surveySession audio recordingsHealth needs
2020
Rapid transitional response to the COVID-19 pandemic by opioid agonist treatment programs in Ukraine
Meteliuk A, Galvez de Leon SJ, Madden LM, Pykalo I, Fomenko T, Filippovych M, Farnum SO, Dvoryak S, Islam ZM, Altice FL. Rapid transitional response to the COVID-19 pandemic by opioid agonist treatment programs in Ukraine. Journal Of Substance Use And Addiction Treatment 2020, 121: 108164. PMID: 33191004, PMCID: PMC7769928, DOI: 10.1016/j.jsat.2020.108164.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyTake-home dosingInterim guidanceShort-term overall mortalityOpioid agonist treatment programPerson clinical encountersOAT deliveryAgonist therapyOverall mortalityCOVID-19 transmissionPatient dropoutOAT patientsNaloxone distributionOverdose educationClinical practiceClinic interactionsTreatment programClinical encountersPatientsCliniciansCOVID-19COVID-19 pandemicOverdosesDosingPrevious yearThe real‐world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine
Farnum SO, Makarenko I, Madden L, Mazhnaya A, Marcus R, Prokhorova T, Bojko MJ, Rozanova J, Dvoriak S, Islam Z, Altice FL. The real‐world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine. Addiction 2020, 116: 83-93. PMID: 32428276, PMCID: PMC7674222, DOI: 10.1111/add.15115.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyOAT discontinuationAgonist therapyTreatment retentionIndependent predictorsHIV epidemicCost-effective HIV prevention strategyMethadone maintenance treatment patientsObservational longitudinal cohort studySpecialty addictions treatmentBuprenorphine maintenance treatmentHigh dosageHIV prevention strategiesLongitudinal cohort studyOpioid-dependent peopleTreatment discontinuationCohort studyMaintenance treatmentMale sexTreatment patientsPrevention strategiesDiscontinuationYounger ageCenter settingAddiction treatmentCorrelates of sleep quality and excessive daytime sleepiness in people with opioid use disorder receiving methadone treatment
Baldassarri SR, Beitel M, Zinchuk A, Redeker NS, Oberleitner DE, Oberleitner LMS, Carrasco D, Madden LM, Lipkind N, Fiellin DA, Bastian LA, Chen K, Yaggi HK, Barry DT. Correlates of sleep quality and excessive daytime sleepiness in people with opioid use disorder receiving methadone treatment. Sleep And Breathing 2020, 24: 1729-1737. PMID: 32556918, PMCID: PMC7680294, DOI: 10.1007/s11325-020-02123-z.Peer-Reviewed Original ResearchConceptsOpioid use disorderExcessive daytime sleepinessDaytime sleepinessSleep qualityChronic painExcessive daytimeUse disordersConclusionsPoor sleep qualityCurrent chronic painModifiable risk factorsImpaired sleep qualityMultivariable linear regression modelsBody mass indexPoor sleep qualityNon-significant associationMass indexMultivariable analysisPain interferenceRelated comorbiditiesMethadone treatmentClinical correlatesMean PSQIRisk factorsSleep disordersResultsNinety percentThe Balanced Opioid Initiative: protocol for a clustered, sequential, multiple-assignment randomized trial to construct an adaptive implementation strategy to improve guideline-concordant opioid prescribing in primary care
Quanbeck A, Almirall D, Jacobson N, Brown RT, Landeck JK, Madden L, Cohen A, Deyo BMF, Robinson J, Johnson RA, Schumacher N. The Balanced Opioid Initiative: protocol for a clustered, sequential, multiple-assignment randomized trial to construct an adaptive implementation strategy to improve guideline-concordant opioid prescribing in primary care. Implementation Science 2020, 15: 26. PMID: 32334632, PMCID: PMC7183389, DOI: 10.1186/s13012-020-00990-4.Peer-Reviewed Original ResearchConceptsOpioid prescribing practicesPrimary care clinicsPractice facilitationPrescribing practicesPrimary careOpioid prescribingMonth 3Primary outcomeCare clinicsDifferent primary care clinicsDiverse primary care clinicsHybrid type 3Study's primary outcomeDifferent clinical settingsPrimary aimCost-effective sequenceOpioid misuseEvidence-based practiceMonth 21Study's primary aimClinical guidelinesImplementation strategiesOverdose deathsDesignThe studyAdaptive implementation strategy
2019
Effect of expanding opioid agonist therapies on the HIV epidemic and mortality in Ukraine: a modelling study
Tan J, Altice FL, Madden LM, Zelenev A. Effect of expanding opioid agonist therapies on the HIV epidemic and mortality in Ukraine: a modelling study. The Lancet HIV 2019, 7: e121-e128. PMID: 31879250, PMCID: PMC7289179, DOI: 10.1016/s2352-3018(19)30373-x.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyNew HIV infectionsHigh HIV burdenHIV infectionMinistry of HealthOAT coverageAgonist therapyHIV burdenHIV incidenceBuprenorphine maintenance therapyPublic Health CenterMaintenance therapyHIV outcomesHIV prevalenceHIV transmissionMedication procurementHIV epidemicHealth centersHIV preventionTreatment goalsPWIDOAT expansionDisease controlSexual riskInfection
2018
An evaluation of the feasibility, acceptability, and preliminary efficacy of cognitive-behavioral therapy for opioid use disorder and chronic pain
Barry DT, Beitel M, Cutter CJ, Fiellin DA, Kerns RD, Moore BA, Oberleitner L, Madden LM, Liong C, Ginn J, Schottenfeld RS. An evaluation of the feasibility, acceptability, and preliminary efficacy of cognitive-behavioral therapy for opioid use disorder and chronic pain. Drug And Alcohol Dependence 2018, 194: 460-467. PMID: 30508769, PMCID: PMC6312460, DOI: 10.1016/j.drugalcdep.2018.10.015.Peer-Reviewed Original ResearchConceptsOpioid use disorderCognitive behavioral therapyChronic painPreliminary efficacyDrug counselingUse disordersImproved pain outcomesProportion of patientsMethadone-maintained patientsNonmedical opioid useEnd of treatmentPrimary study aimPatient satisfaction ratingsManualized cognitive behavioral therapyOpioid usePain outcomesPain interferenceClinical trialsStandard drug counselingPatientsMean sessionSecondary aimStudy aimPainPilot study